 "NTAGI meeting on vaccination for 5-12-year-olds inconclusive: Sources")
India’s vaccine think-tank the National Technical Advisory Group on Immunisation (NTAGI) meeting to discuss vaccination protocol for 5-12 year old kids remained inconclusive on Wednesday, according to sources.
The NTAGI members reviewed data from vaccine makers for 5-12 year old kids, but no decision on whether to expand the program to this younger group was taken.
Last month the regulator had approved two vaccines--Serum Institute's Covovax and Biological E-made Corbevax--for use in 5-12-year-old children.
However the NTAGI decides on whether these would be used in India's Covid-19 vaccination programme.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%